THC FARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.043 USD | +167.08% |
|
+167.08% | +95.45% |
| 2023 | THC Farmaceuticals, Inc. announced that it expects to receive $0.124 million in funding | CI |
| 2021 | Thc Farmaceuticals, Inc. Announces Final Departure of Mike Gravel, Chairman | CI |
Financials (USD)
| Sales 2013 | 21.64K | Sales 2014 | 19.03K | Capitalization | 9.86M |
|---|---|---|---|---|---|
| Net income 2013 | - | Net income 2014 | - | EV / Sales 2013 * | - |
| Net Debt 2013 | 58.16K | Net Debt 2014 | 77.06K | EV / Sales 2014 | 522 x |
| P/E ratio 2013 * |
-
| P/E ratio 2014 |
-321
x | Employees | - |
| Yield 2013 * |
-
| Yield 2014 |
-
| Free-Float | 20.62% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +167.08% | ||
| 1 week | +167.08% | ||
| Current month | +255.37% | ||
| 1 month | +159.04% | ||
| 3 months | +175.64% | ||
| 6 months | +283.93% | ||
| Current year | +95.45% |
1 week
0.04
0.04
1 month
0.010.04
Current year
0.000.07
1 year
0.000.10
3 years
0.000.35
5 years
0.000.84
10 years
0.008.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mark Grossman
CEO | Chief Executive Officer | - | - |
Gary Henrie
LAW | General Counsel | 70 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Tobias
BRD | Director/Board Member | 73 | - |
Mark Grossman
CEO | Chief Executive Officer | - | - |
THC Farmaceuticals, Inc. is a clinical-stage biotechnology company. The Company specializes in the discovery, development, and commercialization of novel cannabinoid-based products in dental, ophthalmology and other medical disciplines. It offers the combination of its proprietary developments with its clinicians and scientists to unlock the therapeutic properties of cannabis and its bioactive compounds. The Company owns clinical research center and cannabidiol (CBD) manufacturing facility in California. Its business plan includes conducting cannabinoids research and development in collaboration with cannabis research centers worldwide with the goal of developing novel and advanced therapeutic methods for the treatment of common medical conditions with cannabis-based therapies and to conduct pre-clinical investigations and randomized, placebo-controlled trials of CBD-based compounds and develop condition-specific medications. It offers a network of micro vending kiosk systems.
Sector
Drug Retailers
| 1st Jan change | Capi. | |
|---|---|---|
| +95.45% | 780K | |
| +8.14% | 2.78B | |
| +9.01% | 1.61B | |
| +81.18% | 613M | |
| -0.91% | 464M | |
| +30.99% | 162M | |
| +13.51% | 110M | |
| -2.77% | 101M | |
| +50.56% | 56.08M |
- Stock Market
- Equities
- CBDG Stock
